PAM
CGEM icon

Panagora Asset Management’s Cullinan Oncology CGEM Stock Holding History

Panagora Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$444K Buy
+24,396
New +$362K ﹤0.01% 924

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Panagora Asset Management's CGEM Position: Q2 2026 in Review

Panagora Asset Management opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 24,396 shares worth $444K. The stake represents ﹤0.01% of the portfolio and ranks #924 among its holdings.

183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Panagora Asset Management held 24,396 shares of Cullinan Oncology worth $444K as of Q2 2026.
  • Cullinan Oncology was a new Panagora Asset Management position in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #924 holding.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.